HC Wainwright & Co. Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $83
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has maintained a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and increased the price target from $73 to $83.
March 04, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ANI Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., with the price target raised from $73 to $83.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong confidence in the company's future performance. This can lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100